Cotinga Pharmaceuticals Inc. (COTQF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2018 | 148.65 Thousand USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 316.11 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2019 Q2 | 259.56 USD | 80.98% |
| 2019 Q1 | 143.42 USD | -3.92% |
| 2019 Q3 | 354.87 USD | 36.72% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | 149.26 USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 148.65 Thousand USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q3 | 314.52 USD | -6.92% |
| 2014 FY | - USD | -100.0% |
| 2014 Q2 | 337.90 USD | 1.07% |
| 2014 Q4 | - USD | -100.0% |
| 2014 Q1 | 334.30 USD | 5.76% |
| 2013 Q4 | 316.11 USD | 0.0% |
| 2013 FY | 316.11 Thousand USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.639% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 96.394% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.459% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.657% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.501% |
| Mesoblast Limited | 118.7 Million USD | 99.875% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 84.324% |
| Genus plc | 233.1 Million USD | 99.936% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 94.927% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 88.936% |
| Marizyme, Inc. | 18.71 Million USD | 99.206% |
| ContraFect Corporation | 2.88 Million USD | 94.84% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 80.179% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -9.718% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 89.722% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 93.609% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 97.373% |
| MultiCell Technologies, Inc. | 202.58 USD | -73280.393% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.741% |
| EV Biologics, Inc. | 1.49 Million USD | 90.055% |
| Q BioMed Inc. | 4.1 Million USD | 96.383% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.551% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 76.407% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 87.898% |
| Biomind Labs Inc. | 735.54 Thousand USD | 79.79% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.913% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.856% |
| Skye Bioscience, Inc. | 4.61 Million USD | 96.779% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 83.261% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -5.042% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 97.468% |
| IMV Inc. | 28.88 Million USD | 99.485% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -477.993% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 93.418% |
| GB Sciences, Inc. | 1.75 Million USD | 91.55% |
| Alpha Cognition Inc. | 1.22 Million USD | 87.819% |
| HST Global, Inc. | 98.31 Thousand USD | -51.196% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Halberd Corporation | 150 Thousand USD | 0.897% |
| Enzolytics Inc. | 996.33 Thousand USD | 85.08% |
| Resverlogix Corp. | 6.49 Million USD | 97.71% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 68.868% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 41.839% |
| argenx SE | 20 Million USD | 99.257% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.674% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 94.512% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1353.829% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.964% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 25.901% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 93.8% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 35.168% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.78% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 95.088% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 58.674% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.269% |
| BioStem Technologies, Inc. | 4.71 Million USD | 96.845% |
| ONE Bio Corp. | 19.71 Million USD | 99.246% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 40.582% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 40.232% |
| Agentix Corp. | 50 Thousand USD | -197.308% |
| LadRx Corporation | 33.6 Thousand USD | -342.344% |
| Cell Source, Inc. | 9.25 Million USD | 98.394% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 80.342% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 80.342% |
| NovAccess Global Inc. | 2.19 Million USD | 93.243% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.898% |
| Itoco Inc. | 228.37 Thousand USD | 34.909% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 29.54% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 97.017% |
| Kadimastem Ltd | 891.22 Thousand USD | 83.32% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 63.007% |
| CytoDyn Inc. | 30.07 Million USD | 99.506% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 69.304% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 57.75% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 98.099% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -21.35% |
| Rebus Holdings, Inc. | 310 Thousand USD | 52.047% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 96.861% |
| International Stem Cell Corporation | 4.17 Million USD | 96.442% |
| Bioxytran, Inc. | 1.92 Million USD | 92.278% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -138.178% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93.184% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 98.212% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 98.268% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 90.443% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 44.532% |
| Neutra Corp. | 54.15 Thousand USD | -174.492% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 91.877% |
| PureTech Health plc | 25.51 Million USD | 99.417% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 87.857% |
| IXICO plc | 472.02 Thousand USD | 68.507% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.041% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.761% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.84% |